Matching articles for "glioma"
Vorasidenib (Voranigo) for Low-Grade Glioma (online only)
The FDA has approved vorasidenib ( Voranigo – Servier), an oral isocitrate dehydrogenase (IDH) inhibitor, for treatment of grade 2 astrocytoma or oligodendroglioma in patients ≥12 years old with an IDH1 or…
Med Lett Drugs Ther. 2024 Nov 11; 66(1715):e188-9 doi:10.58347/tml.2024.1715g
The FDA has approved vorasidenib ( Voranigo – Servier), an oral isocitrate dehydrogenase (IDH) inhibitor, for treatment of grade 2 astrocytoma or oligodendroglioma in patients ≥12 years old with an IDH1 or IDH2 mutation. It is the first systemic treatment to be approved in the US for this indication.
Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)
Tovorafenib ( Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade…
Med Lett Drugs Ther. 2024 Jun 10; 66(1704):e97-8 doi:10.58347/tml.2024.1704f
Tovorafenib ( Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or a BRAF V600 mutation. Tovorafenib is the first systemic treatment to be approved in the US for pediatric low-grade gliomas with BRAF fusions. Accelerated approval of tovorafenib was based on response rates and duration of response.
In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)
The oral kinase inhibitors dabrafenib ( Tafinlar – GSK) and trametinib ( Mekinist – Novartis) have been approved by the FDA for use together for a sixth indication: treatment of low-grade glioma (LGG) with…
Med Lett Drugs Ther. 2023 Apr 17; 65(1674):e75-6 doi:10.58347/tml.2023.1674i
The oral kinase inhibitors dabrafenib ( Tafinlar – GSK) and trametinib ( Mekinist – Novartis) have been approved by the FDA for use together for a sixth indication: treatment of low-grade glioma (LGG) with a BRAF V600E mutation in patients ≥1 years old who require systemic therapy. This combination is the first systemic therapy to be approved in the US for first-line treatment of LGG with a BRAF V600E mutation in pediatric patients. The FDA also approved new oral formulations of both drugs for patients who are unable to swallow dabrafenib capsules or trametinib tablets.
